Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Theratechnologies Inc. (THER) Message Board

Theralink® Technologies Announces Milestone Event

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 110
(Total Views: 414)
Posted On: 01/30/2021 2:32:24 AM
Avatar
Posted By: Mauibound
Theralink® Technologies Announces Milestone Event--The Commencement of Testing on its First Patients

PR Newswire

DENVER , Jan. 27, 2021 /PRNewswire/ -- Theralink® Technologies (OTC: OBMP) ("Theralink" or the "Company"  , a precision medicine molecular profiling company with a novel phosphoprotein-based Laboratory Developed Test (LDT), today announced that it has begun the testing of its first patients with the Theralink's Reverse Phase Protein Array (RPPA) technology. Theralink's RPPA testing measures the direct activation state for dozens of drug targets at once potentially providing oncologists with key information about the patient's specific tumor. Theralink's unique assay is the only commercial LDT assay on the market that can measure the activation/phosphorylation state of dozens of drug targets directly from a tumor biopsy.

"We are pleased to have launched Theralink's RPPA testing with Dr. Matthew Schwartz , who is a radiation oncologist with Comprehensive Cancer Centers of Nevada . With our unique molecular profiling assay, that goes beyond a genomics-only approach, physicians throughout the country, with the exceptions below, will have access to potentially critically missing and actionable information to help them make time-sensitive treatment decisions for their patients," said Mick Ruxin , M.D., President & CEO of Theralink.

The initial use for the Theralink assay for breast cancer is for patients with:

Late Stage (stage III-IV) Triple Negative Breast CancerLate Stage (stage III-IV) HER2+ Breast CancerLate Stage (stage III-IV) ER+/HER2- Breast CancerMetastatic Breast CancerInflammatory Breast Cancer

Theralink is now accepting patients' breast cancer tumor biopsies from all physicians across the US except those physicians located in New York and California , which will be accepted upon Clinical Laboratory Improvement Amendments (CLIA) certification from those two states.

Theralink's patented RPPA testing is designed to provide new protein and phosphoprotein biomarkers through the direct and quantitative measurement of the expression levels of a protein drug target and pathways surrounding it. This testing gives physicians data-driven support to help them make decisions and help them enable new predictive protein biomarker-based therapy selection. Theralink can measure the activation state of key drug targets and signaling pathways within a microscopic quantity of tumor sample.

"The Theralink assay for breast cancer may reveal therapeutic options for oncologists and in turn, may provide better outcomes for breast cancer patients. Theralink's testing is initially for breast cancer, but we plan to offer the Theralink assay for numerous other cancer types in the near future," concluded Dr. Ruxin.

About Theralink Technologies, Inc.

Theralink Technologies is a proteomics-based, molecular profiling and precision medicine company with a CLIA-certified laboratory located in Golden, Colorado . Through its unique and patented phosphoprotein and protein biomarker platform and LDTs, Theralink's technology targets multiple areas of oncology and drug development. Theralink provides precision oncology data through its powerful Theralink® Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to both FDA-approved and investigational drug treatments. Theralink intends to help improve cancer outcomes for patients, reveal therapeutic options for oncologists, and support biopharmaceutical drug development by using a beyond-genomics approach to molecular profiling that directly measures drug target levels and activity. For more information, please visit
www.theralink.com

https://investorshangout.com/recentnews/OBMP#ixzz6l0w4SJ2K


(0)
(0)




Theratechnologies Inc. (THER) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us